Table II.
Descriptive data for peakVO2% for all study subjects with Fabry disease (FD) at first, second, and third years of evaluation
| Year of evaluation | Patients | peakVO2, % Mean (SD) | 95% CI |
|---|---|---|---|
| 1 | Total | 80.10 (17.16) | 70.33-90.20 |
| CL-FD group | 77.02 (14.45) | 64.23-83.27 | |
| CV-FD group | 85.97 (21.16) | 60.57-96.12 | |
| 2 | Total | 76.89 (14.72) | 66.54-84.06 |
| CL-FD group | 77.98 (12.97) | 68.62-86.18 | |
| CV-FD group | 78.98 (18.83) | 58.25-94.85 | |
| 3 | Total | 78.78 (12.72) | 71.29-82.65 |
| CL-FD group | 84.75 (5.02) | 80.93-87.91 | |
| CV-FD group | 73.51 (18.15) | 52.61-87.89 |
peakVO2%: percentage of measured peak oxygen consumption to predicted value; 95% CI: 95% confidence interval; CL-FD: classic Fabry disease; CV-FD: cardiac variant Fabry disease; SD: standard deviation.